Headache News and Research

Latest Headache News and Research

Alcohol consumption, cigarette smoking associated with teen migraines, TTH : Study

A novel study by German researchers reported that alcohol consumption and cigarette smoking were associated with increased migraines and tension-type headaches in high school students. Coffee drinking and physical inactivity were associated specifically with migraines. Results of this study, the first to investigate modifiable risk factors for different types of headaches in a youth population, appear online early in Headache, a journal published by Wiley-Blackwell on behalf of the American Headache Society.

7 Jun 2010

Celgene reports initial data from investigator-initiated study of REVLIMID

Celgene International Sàrl today announced that initial data from an investigator-initiated study of REVLIMID (lenalidomide) plus Rituxan (rituximab) in patients with newly diagnosed indolent B-cell non-Hodgkin's lymphoma (NHL) were presented at the annual meeting of the American Society of Clinical Oncology.

5 Jun 2010

Water is essential but electrolyte drinks are needed when exercising in heat

Water is essential when exercising in the heat but it might not be enough to keep you healthy in Houston summers.

5 Jun 2010

Prismatic eyeglass lenses reduce symptoms associated with TBI, vertical heterophoria: Study

A recent retrospective study by four Michigan physicians shows strong evidence that symptoms of headache, dizziness and anxiety in some patients with traumatic brain injury potentially could be alleviated or even eliminated with specialized eyeglass lenses containing prisms.

5 Jun 2010

Researchers present clinical outcomes of lenalidomide in patients with large B-cell lymphoma

Celgene International Sàrl today announced researchers at the annual meeting of the American Society of Clinical Oncology presented data from an evaluation of lenalidomide (REVLIMID) in patients with diffuse large B-cell lymphoma either with a germinal center B-cell or non-germinal center B-cell phenotype.

5 Jun 2010

Coffee consumption not related to alertness

The stimulatory effects of caffeine may be nothing more than an illusion according to new research, which shows there is no real benefit to be gained from the habitual morning cup of coffee.

4 Jun 2010

Antiemetic-regimen with fosaprepitant injection provides similar protection against CINV as oral EMEND

Merck announced today results from a new non-inferiority trial of an antiemetic regimen containing fosaprepitant dimeglumine administered as a single intravenous (IV) 150-mg dose in combination with a 5-HT3 antagonist and dexamethasone compared with a three-day regimen of aprepitant with a 5-HT3 antagonist and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving a first cycle of cisplatin-based chemotherapy.

4 Jun 2010

Morria Biopharmaceuticals to present Phase II study results of MRX-4 at EAACI Congress

Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on novel, anti-inflammatory drugs, announced today that it will be presenting the results from its ICH compliant Phase II study of MRX-4>th EAACI Congress in London on June 7th. The results will be presented by the study's principal investigator Prof. Eric Bateman.

4 Jun 2010

Phase II trial of NUVIGIL Tablets for treatment of schizophrenia fails to meet primary endpoint: Cephalon

Cephalon, Inc. today announced that the primary endpoint was not met in a Phase II clinical trial that examined NUVIGIL (armodafinil) Tablets [C-IV] as an adjunctive therapy for the treatment of the negative symptoms of schizophrenia, which include problems with motivation and emotional withdrawal.

3 Jun 2010

FDA accepts Eisai's NDA for rabeprazole sodium extended-release 50 mg

Eisai Inc. (Headquarters: Woodcliff Lake, NJ; Chairman and CEO: Hajime Shimizu), a U.S. subsidiary of Eisai Co., Ltd. (Headquarters: Tokyo; President and CEO: Haruo Naito) today announced that the U.S. Food and Drug Administration has accepted Eisai's New Drug Application for rabeprazole sodium extended-release 50 mg for the healing and maintenance of healing of erosive gastroesophageal reflux disease, and for the treatment of symptomatic GERD.

3 Jun 2010

Alexion Pharmaceuticals plans to launch Soliris in Japan for patients with PNH

Alexion Pharmaceuticals, Inc. and Alexion Pharma International Sàrl today announced that the launch of Soliris (eculizumab) as a treatment for patients with PNH in Japan will begin in the third quarter of 2010, approximately three months earlier than previously expected.

2 Jun 2010

Phase 3 pivotal REVIVE study data of VIVUS' avanafil for ED presented at 2010 AUA

VIVUS, Inc. today announced that data from the previously reported phase 3 pivotal REVIVE (TA-301) study, evaluating the safety and efficacy of the investigational drug avanafil for the treatment of erectile dysfunction (ED), were presented at the American Urological Association (AUA) 2010 Annual Meeting.

2 Jun 2010

Dendreon announces data presentation from 4 PROVENGE clinical trials at 105th AUA annual meeting

Dendreon Corporation today announced the presentation of safety data from the integrated analysis of four randomized PROVENGE® (sipuleucel-T) clinical trials of an autologous cellular immunotherapy in prostate cancer at the 105th Annual Scientific Meeting of the American Urological Association (AUA) in San Francisco.

1 Jun 2010

FDA warns consumers not to purchase or use Arrow Brand Medicated Oil & Embrocation

The U.S. Food and Drug Administration today warned consumers not to purchase or use a product called "Arrow Brand Medicated Oil & Embrocation," also labeled as "Aceite Medicinal La Flecha (Spanish) or "箭嘜驅風油 (Mandarin)." The product is potentially toxic and contains two substances, methyl salicylate and camphor, which are poisonous when ingested.

29 May 2010

New study holds promise for patients with LCA

A new study led by Dr. Robert Koenekoop at the Montreal Children's Hospital at the McGill University Health Centre holds promise for certain patients with Leber congenital amaurosis, an inherited retinal degenerative disease that causes significant vision loss from birth. The study, sponsored by Canadian company QLT Inc., is designed to treat patients with LCA due to genetic mutations in either retinal pigment epithelium protein 65 or lecithin:retinol acyltransferase.

27 May 2010

EMEND indication helps women prevent CINV

More women fighting cancers such as breast, lung, colorectal and ovarian can now help prevent the nausea and vomiting associated with their treatment of moderately emetogenic (vomit-inducing) cancer chemotherapy. Although new treatment entities have been developed in the past 10 years for control of chemically-induced nausea and vomiting, CINV remains a significant problem in the context of current practice.

26 May 2010

Study demonstrates efficacy of CONCERTA in treating ADHD in presence of comorbid learning disability

Turning in assignments, following instructions and focusing on learning something new are among the daily classroom challenges for children with Attention Deficit Hyperactivity Disorder (ADHD), according to the National Institute of Mental Health (NIMH). New data presented today show efficacy of CONCERTA® (OROS® methylphenidate HCl Extended-Release Tablets CII) on ADHD symptoms in children with the condition who also may face other specific challenges.

26 May 2010

Shire announces study results of Vyvanse Capsules CII for treatment of ADHD in adolescents

Shire plc, the global specialty biopharmaceutical company, today announced the results of a study evaluating the safety and efficacy of Vyvanse (lisdexamfetamine dimesylate) Capsules CII for the treatment of Attention Deficit Hyperactivity Disorder in adolescents aged 13 to 17 years.

26 May 2010

Positive results reported from Phase IIa clinical trial of intranasal oxytocin for CDH

Trigemina, Inc., a Mountain View based privately-held biopharmaceutical company, reports positive results from a time-based interim analysis of its Phase IIa clinical trial in Chronic Daily Headache. The trial is a collaborative effort between Trigemina and Dr. Egilius Spierings of MedVadis Research Corporation located outside of Boston. The study compares intranasal oxytocin with placebo in patients suffering from CDH.

26 May 2010

Vertex reports 75% patients with HCV achieve viral cure with 12-week telaprevir-based combination regimen

Vertex Pharmaceuticals Incorporated today announced that 75% of people chronically infected with genotype 1 hepatitis C virus (HCV) who had not previously been treated achieved a sustained viral response (SVR or viral cure) after receiving a 12-week telaprevir-based combination regimen, followed by treatment with pegylated-interferon and ribavirin alone, in the Phase 3 ADVANCE trial.

26 May 2010

Headache News and Research

Latest Headache News and Research

Alcohol consumption, cigarette smoking associated with teen migraines, TTH : Study

Celgene reports initial data from investigator-initiated study of REVLIMID

Water is essential but electrolyte drinks are needed when exercising in heat

Prismatic eyeglass lenses reduce symptoms associated with TBI, vertical heterophoria: Study

Researchers present clinical outcomes of lenalidomide in patients with large B-cell lymphoma

Coffee consumption not related to alertness

Antiemetic-regimen with fosaprepitant injection provides similar protection against CINV as oral EMEND

Morria Biopharmaceuticals to present Phase II study results of MRX-4 at EAACI Congress

Phase II trial of NUVIGIL Tablets for treatment of schizophrenia fails to meet primary endpoint: Cephalon

FDA accepts Eisai's NDA for rabeprazole sodium extended-release 50 mg

Alexion Pharmaceuticals plans to launch Soliris in Japan for patients with PNH

Phase 3 pivotal REVIVE study data of VIVUS' avanafil for ED presented at 2010 AUA

Dendreon announces data presentation from 4 PROVENGE clinical trials at 105th AUA annual meeting

FDA warns consumers not to purchase or use Arrow Brand Medicated Oil & Embrocation

New study holds promise for patients with LCA

EMEND indication helps women prevent CINV

Study demonstrates efficacy of CONCERTA in treating ADHD in presence of comorbid learning disability

Shire announces study results of Vyvanse Capsules CII for treatment of ADHD in adolescents

Positive results reported from Phase IIa clinical trial of intranasal oxytocin for CDH

Vertex reports 75% patients with HCV achieve viral cure with 12-week telaprevir-based combination regimen

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Headache News and Research

Latest Headache News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in